BACKGROUND: In Alzheimer disease (AD), systemic inflammation is known to give rise to a delirium. However, systemic inflammation also gives rise to other centrally mediated symptoms in the absence of a delirium, a concept known as sickness behavior. Systemic inflammation is characterized by the systemic production of the proinflammatory cytokines tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6) that mediate immune to brain communication and the development of sickness behavior. OBJECTIVE: To determine if raised serum TNFα or IL-6 are associated with the presence of sickness behavior symptoms, independent of the development of delirium, in a prospective cohort study of subjects with AD. METHODS: A total of 300 subjects with mild to severe AD were cognitively assessed at baseline and a blood sample taken for inflammatory markers. Cognitive assessments, including assessments to detect the development of a delirium, and blood samples were repeated at 2, 4, and 6 months. The development of neuropsychiatric symptoms in the subject with AD over the 6-month follow-up period was assessed independently by carer interview at 2, 4, and 6 months. RESULTS: Raised serum TNFα and IL-6, but not CRP, were associated with an approximately 2-fold increased frequency of neuropsychiatric symptoms characteristic of sickness behavior. These relationships are independent of the development of delirium. CONCLUSIONS: Increased serum proinflammatory cytokines are associated with the presence of symptoms characteristic of sickness behavior, which are common neuropsychiatric features found in AD. This association was independent of the presence of delirium.
BACKGROUND: In Alzheimer disease (AD), systemic inflammation is known to give rise to a delirium. However, systemic inflammation also gives rise to other centrally mediated symptoms in the absence of a delirium, a concept known as sickness behavior. Systemic inflammation is characterized by the systemic production of the proinflammatory cytokines tumor necrosis factor-α (TNFα) and interleukin-6 (IL-6) that mediate immune to brain communication and the development of sickness behavior. OBJECTIVE: To determine if raised serum TNFα or IL-6 are associated with the presence of sickness behavior symptoms, independent of the development of delirium, in a prospective cohort study of subjects with AD. METHODS: A total of 300 subjects with mild to severe AD were cognitively assessed at baseline and a blood sample taken for inflammatory markers. Cognitive assessments, including assessments to detect the development of a delirium, and blood samples were repeated at 2, 4, and 6 months. The development of neuropsychiatric symptoms in the subject with AD over the 6-month follow-up period was assessed independently by carer interview at 2, 4, and 6 months. RESULTS: Raised serum TNFα and IL-6, but not CRP, were associated with an approximately 2-fold increased frequency of neuropsychiatric symptoms characteristic of sickness behavior. These relationships are independent of the development of delirium. CONCLUSIONS: Increased serum proinflammatory cytokines are associated with the presence of symptoms characteristic of sickness behavior, which are common neuropsychiatric features found in AD. This association was independent of the presence of delirium.
Authors: J Monette; G Galbaud du Fort; S H Fung; F Massoud; Y Moride; L Arsenault; M Afilalo Journal: Gen Hosp Psychiatry Date: 2001 Jan-Feb Impact factor: 3.238
Authors: Lucile Capuron; Jane F Gumnick; Dominique L Musselman; David H Lawson; Andrea Reemsnyder; Charles B Nemeroff; Andrew H Miller Journal: Neuropsychopharmacology Date: 2002-05 Impact factor: 7.853
Authors: Colm Cunningham; Suzanne Campion; Katie Lunnon; Carol L Murray; Jack F C Woods; Robert M J Deacon; J Nicholas P Rawlins; V Hugh Perry Journal: Biol Psychiatry Date: 2008-09-18 Impact factor: 13.382
Authors: Ulrich Thiem; David Niklaus; Bettina Sehlhoff; Christoph Stückle; Hans Jürgen Heppner; Heinz Gerd Endres; Ludger Pientka Journal: Age Ageing Date: 2009-09-03 Impact factor: 10.668
Authors: Riccardo E Marioni; Mark W J Strachan; Rebecca M Reynolds; Gordon D O Lowe; Rory J Mitchell; F Gerry R Fowkes; Brian M Frier; Amanda J Lee; Isabella Butcher; Ann Rumley; Gordon D Murray; Ian J Deary; Jackie F Price Journal: Diabetes Date: 2009-12-03 Impact factor: 9.461
Authors: Deborah Doens; Pedro A Valiente; Adelphe M Mfuh; Anh X T Vo; Adilia Tristan; Lizmar Carreño; Mario Quijada; Vu T Nguyen; George Perry; Oleg V Larionov; Ricardo Lleonart; Patricia L Fernández Journal: ACS Chem Neurosci Date: 2017-02-15 Impact factor: 4.418
Authors: Katrin I Andreasson; Adam D Bachstetter; Marco Colonna; Florent Ginhoux; Clive Holmes; Bruce Lamb; Gary Landreth; Daniel C Lee; Donovan Low; Marina A Lynch; Alon Monsonego; M Kerry O'Banion; Milos Pekny; Till Puschmann; Niva Russek-Blum; Leslie A Sandusky; Maj-Linda B Selenica; Kazuyuki Takata; Jessica Teeling; Terrence Town; Linda J Van Eldik Journal: J Neurochem Date: 2016-09 Impact factor: 5.372
Authors: Margarete A Wichmann; Karen J Cruickshanks; Cynthia M Carlsson; Rick Chappell; Mary E Fischer; Barbara E K Klein; Ronald Klein; Michael Y Tsai; Carla R Schubert Journal: J Am Geriatr Soc Date: 2014-08-14 Impact factor: 5.562
Authors: Stephen Blackmore; Jessica Hernandez; Michal Juda; Emily Ryder; Gregory G Freund; Rodney W Johnson; Andrew J Steelman Journal: Proc Natl Acad Sci U S A Date: 2017-07-10 Impact factor: 11.205